Top Journals On HIV Associated Dementia

 Since the introduction of highly active antiretroviral therapy, survival rates for human immunodeficiency virus (HIV) infection have markedly improved, but less of an impact has been found for HIV-associated neurocognitive disorders. On the thought of our earlier findings, we cogitate that increased production of osteopontin might contribute to the persistence of central nervous system dysfunctions. We found increased levels of osteopontin within the brains of humans with HIV encephalitis and monkeys with simian immunodeficiency virus (SIV) encephalitis. In spinal fluid , osteopontin levels were found to be elevated in HIV-infected individuals, no matter their neuropsychological status. However, plasma osteopontin levels were automatically increased in entity with HIV-associated dementia. In addition, a long study of monkeys revealed that plasma levels of osteopontin increased before the event of SIV-induced neurological and clinical abnormalities. Thus, plasma levels of osteopontin are significantly correlated with HIV-induced CNS dysfunction within the present era of efficacious antiviral treatment, and this finding suggests that the event of interventions to modulate osteopontin production or signaling might be beneficial in the prevention or treatment of HIV-induced CNS disorders. HIV-positive patients frequently exhibit a wide range of neurological problems due to the neuropathological events that result from HIV-1 infection itself, as opposed to opportunistic infections. Neurological symptoms associated with HIV can include cognitive impairments, motor disturbances, and behavioral changes. Infection with HIV-1 can induce dementia despite successful administration of life-prolonging highly active antiretroviral therapy.